{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:13:37Z","timestamp":1789596817861,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate the cost effectiveness of universal screening for hepatitis B immunity and vaccination among pregnant women in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We designed a decision-analytic model to evaluate the outcomes, costs, and cost effectiveness associated with universal hepatitis B virus (HBV) immunity screening in pregnancy with vaccination of susceptible individuals compared with no screening. A theoretical cohort of 3.6 million women, the approximate number of annual live births in the United States, was used. Outcomes included cases of HBV, hepatocellular carcinoma, decompensated cirrhosis, liver transplant and death, in addition to cost and quality-adjusted life-years (QALYs). Model inputs were derived from the literature, and the willingness-to-pay threshold was $50,000 per QALY. Univariate sensitivity analyses and Monte Carlo simulation models were performed to evaluate the robustness of the results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>In a theoretical cohort of 3.6 million women, universal HBV immunity screening and vaccination resulted in 1,702 fewer cases of HBV, seven fewer cases of decompensated cirrhosis, four fewer liver transplants, and 11 fewer deaths over the life expectancy of a woman after pregnancy. Universal screening and vaccination were found to be cost effective, with an incremental cost-effectiveness ratio of $1,890 per QALY. Sensitivity analyses demonstrated the model was robust even when the prevalence of HBV immunity was high and the annual risk of HBV acquisition low.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Among pregnant women in the United States, universal HBV immunity screening and vaccination of susceptible persons is cost effective compared with not routinely screening and vaccinating.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004652","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T04:00:30Z","timestamp":1643947230000},"page":"357-367","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy"],"prefix":"10.1097","volume":"139","author":[{"given":"Malavika","family":"Prabhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite K.","family":"Susich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire H.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa R.","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Riley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"R1-20250430","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7326\/M17-1106","article-title":"Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention","volume":"167","author":"Abara","year":"2017","journal-title":"Ann Intern Med"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"e2022388","DOI":"10.1001\/jamanetworkopen.2020.22388","article-title":"Prevalence of hepatitis B vaccination coverage and serologic evidence of immunity among US-born children and adolescents from 1999 to 2016","volume":"3","author":"Le","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R3-20250430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ogc.2014.08.004","article-title":"Prevention and management of viral hepatitis in pregnancy","volume":"41","author":"Rac","year":"2014","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R4-20250430","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2334-14-368","article-title":"Clinical features and outcome of acute hepatitis B in pregnancy","volume":"14","author":"Han","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R5-20250430","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1016\/j.vaccine.2018.08.074","article-title":"Uptake and safety of hepatitis B vaccination during pregnancy: a vaccine safety datalink study","volume":"36","author":"Groom","year":"2018","journal-title":"Vaccine"},{"key":"R6-20250430","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/ciu103","article-title":"Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization","volume":"58","author":"Hechter","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R7-20250430","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/656776","article-title":"Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial","volume":"202","author":"Hwang","year":"2010","journal-title":"J Infect Dis"},{"key":"R8-20250430","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/AOG.0b013e3182148efe","article-title":"Efficacy of an accelerated hepatitis B vaccination program during pregnancy","volume":"117","author":"Sheffield","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R9-20250430","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/AOG.0000000000003706","article-title":"Universal screening and vaccination for hepatitis B in pregnancy: the time is now","volume":"135","author":"Prabhu","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R12-20250430","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1097\/INF.0000000000001516","article-title":"Hepatitis B surface antigen testing among pregnant women, United States 2014","volume":"36","author":"Kolasa","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20250430","first-page":"1","article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents [published erratum appears in MMWR Recomm Rep 2006 55:158\u20139]","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R14-20250430","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.02430-07","article-title":"Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen","volume":"46","author":"Huzly","year":"2008","journal-title":"J Clin Microbiol"},{"key":"R16-20250430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4038\/cmj.v47i1.6396","article-title":"Seroconversion after hepatitis B vaccination in healthy young adults, and the effect of a booster dose","volume":"47","author":"Perera","year":"2002","journal-title":"Ceylon Med J"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.15585\/mmwr.mm6939a2","article-title":"Influenza and Tdap vaccination coverage among pregnant women - United States, April 2020","volume":"69","author":"Razzaghi","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R19-20250430","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/vaccines1020167","article-title":"Hepatitis B vaccination in pregnancy in the United States","volume":"1","author":"Stewart","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/hep.22975","article-title":"Epidemiology of hepatitis B in the United States","volume":"49","author":"Kim","year":"2009","journal-title":"Hepatology"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"S765","DOI":"10.1093\/infdis\/jix356","article-title":"Immunopathogenesis of hepatitis B virus","volume":"216","author":"Tseng","year":"2017","journal-title":"J Infect Dis"},{"key":"R26-20250430","doi-asserted-by":"crossref","first-page":"ofy353","DOI":"10.1093\/ofid\/ofy353","article-title":"Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States","volume":"6","author":"Chahal","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"R27-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cld.732","article-title":"Epidemiology of hepatitis B virus infection in the United States","volume":"12","author":"Hyun Kim","year":"2018","journal-title":"Clin Liver Dis"},{"key":"R28-20250430","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.30501","article-title":"The hepatitis C virus care continuum: linkage to hepatitis C virus care and treatment among patients at an urban health network, Philadelphia, PA","volume":"70","author":"Coyle","year":"2019","journal-title":"Hepatology"},{"key":"R29-20250430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugpo.2016.12.006","article-title":"Using database linkages to monitor the continuum of care for hepatitis C virus among syringe exchange clients: experience from a pilot intervention","volume":"42","author":"Hochstatter","year":"2017","journal-title":"Int J Drug Pol"},{"key":"R30-20250430","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"R31-20250430","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"R32-20250430","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatol"},{"key":"R33-20250430","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/dc12-0759","article-title":"Cost-effectiveness of hepatitis B vaccination in adults with diagnosed diabetes","volume":"36","author":"Hoerger","year":"2013","journal-title":"Diabetes Care"},{"key":"R38-20250430","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amepre.2006.01.017","article-title":"Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites","volume":"30","author":"Kim","year":"2006","journal-title":"Am J Prev Med"},{"key":"R39-20250430","doi-asserted-by":"crossref","first-page":"855","DOI":"10.7326\/0003-4819-127-10-199711150-00001","article-title":"Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C","volume":"127","author":"Bennett","year":"1997","journal-title":"Ann Intern Med"},{"key":"R40-20250430","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1097\/00004836-200411003-00005","article-title":"Cost of chronic hepatitis B infection in the United States","volume":"38","author":"Lee","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R41-20250430","doi-asserted-by":"crossref","first-page":"e00062","DOI":"10.14309\/ctg.0000000000000062","article-title":"Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database","volume":"10","author":"Desai","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"R42-20250430","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ajog.2004.10.600","article-title":"Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis","volume":"192","author":"Plunkett","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"R43-20250430","first-page":"932","article-title":"Cost-effectiveness of a trial of labor after previous cesarean","volume":"97","author":"Chung","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R45-20250430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12962-018-0088-9","article-title":"Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea","volume":"16","author":"Lee","year":"2018","journal-title":"Cost Eff Resour Alloc"},{"key":"R46-20250430","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","article-title":"Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"R47-20250430","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"key":"R48-20250430","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2012\/736452","article-title":"Health state utilities and quality of life in patients with hepatitis B","volume":"26","author":"Woo","year":"2012","journal-title":"Can J Gastroenterol"},{"key":"R49-20250430","doi-asserted-by":"crossref","first-page":"e0221769","DOI":"10.1371\/journal.pone.0221769","article-title":"Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India","volume":"14","author":"Chugh","year":"2019","journal-title":"PLoS One"},{"key":"R50-20250430","doi-asserted-by":"crossref","first-page":"e0221614","DOI":"10.1371\/journal.pone.0221614","article-title":"Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: a modeling study","volume":"14","author":"Uyei","year":"2019","journal-title":"PLoS One"},{"key":"R51-20250430","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jval.2019.09.2751","article-title":"Cost-effectiveness analysis of screening for persistent hepatitis E virus infection in solid organ transplant patients in the United Kingdom: a model-based economic evaluation","volume":"23","author":"Ankcorn","year":"2020","journal-title":"Value Health"},{"issue":"(suppl 5)","key":"R53-20250430","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","article-title":"Infectious diseases and injection drug use: public health burden and response","volume":"222","author":"Levitt","year":"2020","journal-title":"J Infect Dis"},{"key":"R54-20250430","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/OLQ.0000000000001355","article-title":"Sexually transmitted infections among US women and men: prevalence and incidence estimates2018","volume":"48","author":"Kreisel","year":"2021","journal-title":"Sex Transm Dis"},{"key":"R56-20250430","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1016\/j.vaccine.2019.03.050","article-title":"Sociodemographic, clinical and birth hospitalization characteristics and infant hepatitis B vaccination in Washington State","volume":"37","author":"Oster","year":"2019","journal-title":"Vaccine"},{"key":"R57-20250430","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1542\/hpeds.2019-0029","article-title":"Parental refusal of standard-of-care prophylactic newborn practices: in one center's experience, many refuse one but few refuse all","volume":"9","author":"Danziger","year":"2019","journal-title":"Hosp Pediatr"},{"key":"R58-20250430","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1341-8076.2002.00076.x","article-title":"Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy","volume":"29","author":"Gupta","year":"2003","journal-title":"J Obstet Gynaecol Res"},{"key":"R59-20250430","first-page":"1","article-title":"A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies","author":"Susich","year":"2021","journal-title":"J Maternal-Fetal Neonatal Med"},{"key":"R60-20250430","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/cid\/ciz063","article-title":"Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States","volume":"69","author":"Chaillon","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R61-20250430","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/AOG.0000000000003062","article-title":"Short-term effects and long-term cost-effectiveness of universal hepatitis C testing in prenatal care","volume":"133","author":"Tasillo","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R63-20250430","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","article-title":"The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings","volume":"156","author":"Rein","year":"2012","journal-title":"Ann Intern Med"}],"updated-by":[{"DOI":"10.1097\/aog.0000000000004767","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:40:34Z","timestamp":1746081634000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004652"}},"subtitle":["A Cost-Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004652","relation":{"correction":[{"id-type":"doi","id":"10.1097\/AOG.0000000000004767","asserted-by":"object"}]},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"2021-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}